CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Frailty in Older Adults Undergoing Aortic Valve Replacement: The FRAILTY-AVR Study 2019 Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD ESC Clinical Practice Guidelines New-onset atrial fibrillation after PCI and CABG for left main disease: insights from the EXCEL trial and additional studies Adenosine and adenosine receptor-mediated action in coronary microcirculation Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk Impact of SYNTAX Score on 10-Year Outcomes After Revascularization for Left Main Coronary Artery Disease Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Prior Cerebrovascular Disease: Results From the EXCEL Trial Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial
|<<... 124 125 126 127 128 129 130 ...>>|

Review Article2020 Jun 27;9(7):E2020.

JOURNAL： J Clin Med . Article Link

Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome

W Bor, DA Gorog. Keywords: NOAC; ACS; antiplatelet therapy; antithrombotic therapy; atrial fibrillation; dual therapy; oral anticoagulants; percutaneous coronary intervention; triple therapy; vitamin K antagonist

Full Text PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top